This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2020 Mar;52(3):354.

doi: 10.1038/s41588-020-0582-9.

Author Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response

Sankari Nagarajan¹, Shalini V Rao^#^{1

2}, Joseph Sutton^#¹, Danya Cheeseman^#¹, Shanade Dunn³, Evangelia K Papachristou¹, Jose-Enrique Gonzalez Prada¹, Dominique-Laurent Couturier¹, Sanjeev Kumar¹, Kamal Kishore¹, Chandra Sekhar Reddy Chilamakuri¹, Silvia-Elena Glont¹, Emily Archer Goode¹, Cara Brodie¹, Naomi Guppy⁴, Rachael Natrajan⁴, Alejandra Bruna¹, Carlos Caldas¹, Alasdair Russell¹, Rasmus Siersbæk¹, Kosuke Yusa^{3

5}, Igor Chernukhin¹, Jason S Carroll⁶

Affiliations

Affiliations

¹ CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
² Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
³ Wellcome Trust Sanger Institute, Hinxton, UK.
⁴ The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
⁵ Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
⁶ CRUK Cambridge Institute, University of Cambridge, Cambridge, UK. Jason.carroll@cruk.cam.ac.uk.

^# Contributed equally.

PMID: 32005967
DOI: 10.1038/s41588-020-0582-9

Published Erratum

Author Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response

Sankari Nagarajan et al. Nat Genet. 2020 Mar.

. 2020 Mar;52(3):354.

doi: 10.1038/s41588-020-0582-9.

Authors

Sankari Nagarajan¹, Shalini V Rao^#^{1

2}, Joseph Sutton^#¹, Danya Cheeseman^#¹, Shanade Dunn³, Evangelia K Papachristou¹, Jose-Enrique Gonzalez Prada¹, Dominique-Laurent Couturier¹, Sanjeev Kumar¹, Kamal Kishore¹, Chandra Sekhar Reddy Chilamakuri¹, Silvia-Elena Glont¹, Emily Archer Goode¹, Cara Brodie¹, Naomi Guppy⁴, Rachael Natrajan⁴, Alejandra Bruna¹, Carlos Caldas¹, Alasdair Russell¹, Rasmus Siersbæk¹, Kosuke Yusa^{3

5}, Igor Chernukhin¹, Jason S Carroll⁶

Affiliations

¹ CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
² Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
³ Wellcome Trust Sanger Institute, Hinxton, UK.
⁴ The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
⁵ Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
⁶ CRUK Cambridge Institute, University of Cambridge, Cambridge, UK. Jason.carroll@cruk.cam.ac.uk.

^# Contributed equally.

PMID: 32005967
DOI: 10.1038/s41588-020-0582-9

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, Chilamakuri CSR, Glont SE, Archer Goode E, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll JS. Nagarajan S, et al. Nat Genet. 2020 Feb;52(2):187-197. doi: 10.1038/s41588-019-0541-5. Epub 2020 Jan 6. Nat Genet. 2020. PMID: 31913353 Free PMC article.

Publication types

Actions

Grants and funding

20411/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Miscellaneous
- NCI CPTAC Assay Portal